Latest News
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines
Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors
Quick links
Site Directory
Sandoz today has a strong presence on all continents and is well represented in all key generics markets, allowing us to remain close to patients, doctors, healthcare providers and business partners everywhere.